DNA-PLOIDY AND S-PHASE FRACTION IN MEDULLARY CARCINOMA OF THE BREAST - A NOW CYTOMETRIC ANALYSIS USING ARCHIVAL MATERIAL

Citation
L. Pedersen et al., DNA-PLOIDY AND S-PHASE FRACTION IN MEDULLARY CARCINOMA OF THE BREAST - A NOW CYTOMETRIC ANALYSIS USING ARCHIVAL MATERIAL, Breast cancer research and treatment, 29(3), 1994, pp. 297-306
Citations number
53
Categorie Soggetti
Oncology
ISSN journal
01676806
Volume
29
Issue
3
Year of publication
1994
Pages
297 - 306
Database
ISI
SICI code
0167-6806(1994)29:3<297:DASFIM>2.0.ZU;2-X
Abstract
In a population of 110 primary breast cancers with medullary features, registered in the Danish Breast Cancer Cooperative Group (DBCG) from 1977-82, we have determined ploidy and S-phase fraction (SF) by flow c ytometry (FCM) on paraffin embedded tumour tissue. The distribution of DNA ploidy is not different from the distribution described for breas t cancers in general. No difference is found between the subgroups of medullary and non-medullary cancer when using a new simplified histopa thological definition of medullary carcinoma of the breast, recently p roposed by us. When using the definition proposed by Ridolfi et al. in 1977, we find significantly more tumours with aneuploidy and high SF in the groups of typical medullary carcinoma (TMC) and atypical medull ary carcinoma (AMC) than in the small group of non-medullary carcinoma (NMC), which seems a paradox, as patients with NMC have the worst pro gnosis. However, the number of patients in the NMC group is very small , and the percentage of aneuploid tumours is very low. In 84 protocoll ed patients we found no statistically prognostic importance of ploidy or SF, either in the whole group assessed or when stratifying for the histopathological subgroups. However, a prognostic influence of SF can be traced for the non-medullary cancers, according to the new definit ion, but not for the medullary cancers of the breast. The result empha sizes the impression of MC as being biologically different from other histological types of breast cancer.